Abstract
The first gene to be linked to Parkinson’s disease encodes the neuronal protein α-synuclein. Recent mouse and Drosophila models of Parkinson’s disease support a central role for the process of α-synuclein fibrillization in pathogenesis. However, some evidence indicates that the fibril itself may not be the pathogenic species. Our own biophysical studies suggest that a structured fibrillization intermediate or an alternatively assembled oligomer may be responsible for neuronal death. This speculation can now be experimentally tested in the animal models. Such experiments will have implications for the development of new therapies for Parkinson’s disease and related neurodegenerative diseases.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective
Neurotherapeutics Open Access 09 September 2022
-
Single-vesicle imaging quantifies calcium’s regulation of nanoscale vesicle clustering mediated by α-synuclein
Microsystems & Nanoengineering Open Access 29 June 2020
-
Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein Protect Against Diverse α-Synuclein Mediated Dysfunctions
Scientific Reports Open Access 18 November 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dunnett, S. B. & Bjorklund, A. Nature Suppl. 399, A32–A39 (1999).
Dawson, T. M. Cell 101, 115–118 ( 2000).
Forno, L. S. J. Neuropathol. Exp. Neurol. 55, 259– 272 (1996).
Kosaka, K. & Iseki, E. Curr. Opin. Neurol. 9, 271–275 (1996).
Lansbury, P. T. Proc. Natl Acad. Sci. USA 96, 3342– 3344 (1999).
Lansbury, P. T. Neuron 19, 1151–1154 ( 1997).
Tanner, C. M. et al. J. Am. Med. Assoc. 281, 341– 346 (1999).
Polymeropoulos, M. H. et al. Science 276, 2045– 2047 (1997).
Kruger, R. et al. Nat. Genet. 18, 106–108 (1998).
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. Proc. Natl Acad. Sci. USA 95, 6469–6473 (1998).
Engelender, S. et al. Nat Genet. 22, 110– 114 (1999).
Baba, M. et al. Am. J. Pathol. 152, 879– 884 (1998).
Iwai, A. et al. Neuron 14, 467–475 (1995).
Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A. & Lansbury, P. T. Jr. Biochemistry 35, 13709–13715 (1996).
Conway, K. A., Harper, J. D. & Lansbury, P. T. Nat. Med. 4, 1318– 1320 (1998).
Scheller, R. H. & Barchas, J. D. Science 242, 13–14 (1988).
Jensen, P. H., Nielsen, M. S., Jakes, R., Dotti, C. G. & Goedert, M. J. Biol. Chem. 273, 26292–26294 (1998).
George, J. M., Jin, H., Woods, W. S. & Clayton, D. F. Neuron 15, 361–372 (1995).
Abeliovich, A. et al. Neuron 25, 239–252 (2000).
Masliah, E. et al. Science 287, 1265– 1269 (2000).
Feany, M. & Bender, W. Nature 404, 394–398 (2000).
Rochet, J. C. & Lansbury, P. T. Curr. Opin. Struct. Biol. 10, 60–68 (2000).
Harper, J. D., Lieber, C. M. & Lansbury, P. T. Chem. Biol. 4, 951– 959 (1997).
Harper, J. D., Wong, S. S., Lieber, C. M. & Lansbury, P. T. Jr. Chem. Biol. 4, 119– 125 (1997).
Harper, J. D., Wong, S. S., Lieber, C. M. & Lansbury, P. T. Jr. Biochemistry 38, 8972– 8980 (1999).
Conway, K. A., Harper, J. D. & Lansbury, P. T. Jr. Biochemistry 39, 2552–2563 (2000).
Conway, K. A., et al. Proc. Natl Acad. Sci. USA (in the press).
Tompkins, M. M. & Hill, W. D. Brain Res. 775, 24–29 (1997).
Tompkins, M. M., Basgall, E. J., Zamrini, E. & Hill, W. D. Am. J. Pathol. 150, 119–131 (1997).
Forno, L. S. & Langston, J. W. Neurodegeneration 2, 19–24 (1993).
Moechars, D. et al. J. Biol. Chem. 274, 6483– 6492 (1999).
Hsia, A. Y. et al. Proc. Natl Acad. Sci. USA 96, 3228– 3233 (1999).
Chiesa, R., Piccardo, P., Ghetti, B. & Harris, D. A. Neuron 21, 1339–1351 (1998).
Kazemi–Esfarjani, P. & Benzer, S. Science 287, 1837 –1840 (2000).
Leroy, E. et al. Nature 395, 451–452 (1998).
Kitada, T. et al. Nature 392, 605–608 (1998).
Minton, A. P. Curr. Opin. Struct. Biol. 10, 34–39 (2000).
Li, S. H. & Li, X. J. Hum. Mol. Genet. 7, 777–782 (1998).
Scherzinger, E. et al. Proc. Natl Acad. Sci. USA 96, 4604– 4609 (1999).
Wyttenbach, A. et al. Proc. Natl Acad. Sci. USA 97, 2898– 2903 (2000).
Klement, I. A. et al. Cell 95, 41–53 (1998).
Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M. E. Cell 95, 55–66 ( 1998).
Cummings, C. J. et al. Neuron 24, 879–892 (1999).
Cummings, C. J. et al. Nat Genet. 19, 148– 154 (1998).
Kobayashi, Y. et al. J. Biol. Chem. 275, 8772– 8778 (2000).
Faber, P. W., Alter, J. R., MacDonald, M. E. & Hart, A. C. Proc. Natl Acad. Sci. USA 96, 179– 184 (1999).
Yamamoto, A., Lucas, J. J. & Hen, R. Cell 101, 57–66 (2000).
Chai, Y., Koppenhafer, S. L., Bonini, N. M. & Paulson, H. L. J. Neurosci. 19, 10338–10347 (1999).
Acknowledgements
The authors thank the NINDS for their support in the form of a Morris K. Udall Parkinson’s disease research center of excellence at Brigham and Women’s Hospital. The continuing support of the Foundation for Neurologic Diseases (Newburyport, Massachusetts) is also gratefully acknowledged. P.L. thanks the Alzheimer’s Association for a 1999 Zenith award. M.S.G. acknowledges the NIH for support in the form of a postdoctoral traineeship in molecular biology of neurodegeneration. We also thank the following individuals for suggestions concerning the manuscript: Mel Feany, Michael Schlossmacher, Matthew Frosch, Jie Shen, Anne Hart, Ethan Signer and members of the Lansbury laboratory. We also thank Parsa Kazemi–Esfarjani and Mel Feany for sharing their unpublished results and Tomas Ding for supplying the AFM images in Fig. 1.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goldberg, M., Lansbury Jr, P. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease?. Nat Cell Biol 2, E115–E119 (2000). https://doi.org/10.1038/35017124
Issue Date:
DOI: https://doi.org/10.1038/35017124
This article is cited by
-
Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective
Neurotherapeutics (2022)
-
A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson’s disease
Glycoconjugate Journal (2022)
-
Single-vesicle imaging quantifies calcium’s regulation of nanoscale vesicle clustering mediated by α-synuclein
Microsystems & Nanoengineering (2020)
-
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Scientific Reports (2019)
-
Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein Protect Against Diverse α-Synuclein Mediated Dysfunctions
Scientific Reports (2019)